PharmatrophiX

PharmatrophiX is a clinical-stage biopharmaceutical company, co-founded in 2005 by Stanford neurologist Dr. Frank Longo, that develops disease-modifying, small-molecule oral drugs targeting the mechanisms underlying neurodegenerative and other neurological disorders. Its core technology targets neurotrophin receptors — p75, TrkB, and TrkC — that regulate whether neurons and their synapses survive or degenerate. Its lead candidate, LM11A-31, targets the p75 receptor, crosses the blood-brain barrier as an oral pill, and has shown disease modification in preclinical models of Alzheimer's disease, other tauopathies, HIV dementia, and Huntington's disease, as well as promising results in a Phase 2a Alzheimer's clinical trial.